Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Predicting successful biologics tapering in patients with inflammatory arthri-tis: Secondary analyses based on the BIODOPT trial

Uhrenholt L. et al, (2023), British journal of clinical pharmacology

Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post-hoc analysis of clinical trials.

Tanaka Y. et al, (2023), Int j rheum dis

Et tu, Brutinib? Demise of a kinase target in rheumatoid arthritis?

TAYLOR PC., (2023), Lancet rheumatology

Pain in the joints and beyond; the challenge of rheumatoid arthritis

TAYLOR P., (2023), Lancet rheumatology

Disease activity-guided tapering of biologics in patients with inflammatory arthritis: a pragmatic, randomized, open-label, equivalence trial.

Uhrenholt L. et al, (2023), Scand j rheumatol, 1 - 12

Approaches to optimising access to NICE-approved biologic anti-TNFs for patients with rheumatoid arthritis with moderately active disease

TAYLOR PC. et al, (2023), Bmc medicine

Baricitinib safety for events of special interest in populations at risk: analysis from randomised trial data across rheumatologic and dermatologic indications

TAYLOR PC. et al, (2023), Advances in therapy

Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in 4 Phase 3 Clinical Studies

TAYLOR PC. et al, (2023), Rheumatology and therapy

Pathogenesis of chronic chikungunya arthritis: resemblances and links with rheumatoid arthritis

Amaral JK. et al, (2022), Travel medicine and infectious disease

Outcomes following Adalimumab bio-originator to biosimilar switch - a comparison using real-world patient and physician reported data in European countries

TAYLOR PC. et al, (2022), Rheumatology and therapy

Treat-to-target in rheumatoid arthritis: a real-world study of the application and impact of treat-to-target within the wider context of patient management, patient centricity, and advanced therapy use in Europe

TAYLOR PC. et al, (2022), Rmd open

A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19

Bieber T. et al, (2022), Advances in therapy

Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE

Mysler E. et al, (2022), Rheumatology

Rituximab versus tocilizumab and B-cell status in TNF-alpha inadequate-responder rheumatoid arthritis patients: the R4-RA RCT

Humby F. et al, (2022)

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis

Dougados M. et al, (2022), Rmd open

The opportunities and challenges of telemedicine in the management of people with rheumatoid arthritis

TAYLOR P., (2022), Journal of rheumatology

Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes

TAYLOR P. et al, (2022), Therapeutic advances in musculoskeletal disease

Assessing the Relationship of Patient Global Assessment of Disease Activity and Health Related Quality of Life by SF-36 with Other Patient-Reported Outcomes in Rheumatoid Arthritis: Post Hoc Analyses of Data from Phase 3 Trials of Baricitinib

Strand V. et al, (2022), Journal of rheumatology, 49, 833 - 834

Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis Up to 9.3 Years: An Updated Integrated Safety Analysis

Taylor P. et al, (2022), Journal of rheumatology, 49, 832 - 832

Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial

Rivellese F. et al, (2022), Nature medicine

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?